Gearing for further Growth
Actelion Ltd is a biopharmaceutical company with corporate headquarters in Allschwil/Basel, Switzerland, that focuses on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.
Founded in late 1997, Actelion is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. The company currently has two approved drugs on the market.
Actelion’s lead product, Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second marketed product, Zavesca®, was in-licensed from Oxford GlycoSciences. Zavesca® is the only approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder.
At the beginning of 2006, Actelion is evaluating five compounds in clinical development and runs 12 projects in its drug discovery targeting several indications such as cardiovascular, cardiopulmonary, immunological, and infectious diseases, as well as metabolic and central nervous system disorders.
Actelion aims to combine the innovation, entrepreneurial spirit and flexibility of biotech with the financial, risk management, regulatory and commercial discipline of a large pharmaceutical company. By implementing this strategy, the over 1,000 employees of the company leverage their proven ability to discover new compounds and to advance promising drug candidates from research through development to successful commercialization.
The first substantial product sales were generated during 2002, followed by strong growth in annual revenues and a full-year net profit in 2004. In 2005, Actelion posted sales of CHF 647.6 million and an operating profit of CHF 152.3 million.
Actelion’s shares are listed on the SWX Swiss Exchange (ticker symbol: ATLN).
Founded in late 1997, Actelion is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. The company currently has two approved drugs on the market.
Actelion’s lead product, Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second marketed product, Zavesca®, was in-licensed from Oxford GlycoSciences. Zavesca® is the only approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder.
At the beginning of 2006, Actelion is evaluating five compounds in clinical development and runs 12 projects in its drug discovery targeting several indications such as cardiovascular, cardiopulmonary, immunological, and infectious diseases, as well as metabolic and central nervous system disorders.
Actelion aims to combine the innovation, entrepreneurial spirit and flexibility of biotech with the financial, risk management, regulatory and commercial discipline of a large pharmaceutical company. By implementing this strategy, the over 1,000 employees of the company leverage their proven ability to discover new compounds and to advance promising drug candidates from research through development to successful commercialization.
The first substantial product sales were generated during 2002, followed by strong growth in annual revenues and a full-year net profit in 2004. In 2005, Actelion posted sales of CHF 647.6 million and an operating profit of CHF 152.3 million.
Actelion’s shares are listed on the SWX Swiss Exchange (ticker symbol: ATLN).
| 2005 | 2004 | 2003 | 2002 | 2001 | |
| Total revenues | 663.6 | 471.9 | 307.5 | 132.4 | 14 |
| EBIT | 152.3 | 85.6 | (1.7) | (32) | (102.5) |
| Net profit | 125.5 | 87.2 | (9.9) | (52.1) | (122.9) |
| EPS non-diluted | 5.62 | 3.96 | (0.46) | (2.45) | (5.98) |
| Cash from operations | 138.4 | 91.7 | 38.3 | (35.8) | (29.6) |
| Net equity | 321.7 | 158.1 | 54.4 | 50.3 | 96.9 |
| Employees (FTE equivalent) | 1028 | 854 | 660 | 412 | 263 |
CHF mio except per share and employee data
includes discontinued operations
includes discontinued operations
